Acute Myeloid Leukemia Clinical Trial
Official title:
Prospective Controlled Clinical Study of Allogeneic Stem Cell Transplantation With Reduced Conditioning (RICT) Versus Best Standard of Care in Acute Myeloid Leukemia (AML)in First Complete Remission (CR)
This study compares overall survival between patients with acute myeloid leukemia, who are in
complete remission following initial treatment with chemotherapy and whose remission is
maintained either with a transplantation of stem cells obtained from a sibling or unrelated
donor or with standard treatment, which is additional chemotherapy.
The study hypothesis is that the group transplanted with stem cells from a donor will have a
superior survival compared with patients treated with standard of care.
Objectives:
The primary objective of this study is to determine whether RICT leads to an improved overall
survival compared to conventional treatment for AML.
The secondary objectives of this study are to determine if:
- RICT leads to a superior long-term overall survival compared to conventional therapy.
- RICT leads to a superior disease-free survival compared to conventional therapy.
- Time to relapse is different between RICT and control groups.
- Quality of life is different between the two treatment groups.
- in RICT patients only:
- Safety and feasibility of the procedure
- Incidence and severity of acute and chronic Graft versus Host Disease (GvHD)
- Rate of complete and partial chimerism
Study Population:
- Newly diagnosed patients with de novo or secondary AML, intermediate or poor risk, in
first complete remission aged 51-70 years.
- Not planned for a full-dose allogeneic transplant.
- According to the investigator, fit for a RICT if a suitable donor (sibling or unrelated)
is found, and also fit for further consolidation chemotherapy in case no suitable donor
is found.
Procedures:
Patients will receive induction therapy according to institutional practice and can be
included after achieving complete remission. Patients for whom a full-dose conditioned
allogeneic transplantation is planned will not be approached, neither will patients who are
for other reasons judged to be ineligible for a RICT. Eligible patients will be informed
about the study. After the patient's consent has been obtained, potential sibling donor(s)
will be briefly informed about the study and asked if they are willing to undergo HLA-typing.
Siblings with evident contraindications to granulocyte colony stimulating factor (G-CSF) or
collection of peripheral blood stem cells should not proceed to HLA-typing. A search for an
unrelated matched donor (MUD) will be initiated if there is no potential sibling donor, or if
sibs are not HLA-identical or otherwise not fit for the donation procedure. A patient's
inclusion in the study is when blood sampling for tissue typing (HLA-typing) of the first
potential sibling donor is made, or when a search warrant for a MUD is dispatched.
- Note: To enable an early donor search, patients may be registered, but not included, for
the study prior to CR. These patients will be included at date of achieved CR.
Registered patients not achieving CR will not be included.
Included patients with a HLA-identical sibling or with an identified MUD will be assigned to
the RICT group, and included patients without such a donor will automatically be in the
control group. This is a HLA-based assignment, and the final intent-to-treat analysis will be
based on the treatment assignment.
After treatment assignment, patients on the control arm should receive consolidation therapy
as per institutional practice, whereas patients on the RICT arm may proceed directly to RICT
or receive one or maximum two consolidation courses. Patients should be in complete remission
at the time of transplant. All patients will be followed for relapse and survival for a
period of at least three years.
The inclusion of 352 patients in complete remission provides a statistical power of 90 % to
detect a difference in overall survival at three years of 20 percentage points, ie from 30 %
of control patients to 50 % in RICT patients.
Inclusion was terminated 2016-07-19 after 360 registered patients. However, some pts were
excluded due to grave protocol deviations or withdrawn consent. The data base was locked in
June 2018 for analysis with 309 pts (after exclusions). Follow-up was >2 yrs fo all pts.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |